(Q35627273)

9 August 2017

title

Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels (English)

1 reference

inflammatory bowel diseases

9 August 2017

0 references

0 references

author name string

Anssi Hämäläinen

series ordinal

1

1 reference

9 August 2017

Taina Sipponen

series ordinal

2

1 reference

9 August 2017

Kaija-Leena Kolho

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

World Journal of Gastroenterology

9 August 2017

published in

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

47

1 reference

9 August 2017

page(s)

5166-5171

1 reference

High-sensitivity C-reactive protein in paediatric inflammatory bowel disease

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Fecal lactoferrin: a new parameter to monitor infliximab therapy.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Classification of inflammatory bowel disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Faecal calprotectin in children with clinically quiescent inflammatory bowel disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Outcome following infliximab therapy in children with ulcerative colitis

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3243882

Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease

15 November 2018

1 reference

12 December 2020

Infliximab dose intensification in Crohn's disease

1 reference

12 December 2020

Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease

1 reference

12 December 2020

Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings

1 reference

12 December 2020

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices

1 reference

12 December 2020

Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease

1 reference

12 December 2020

Infliximab for ulcerative colitis in children and adolescents

1 reference

12 December 2020

Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease

1 reference

12 December 2020

Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease

1 reference

12 December 2020

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

1 reference

12 December 2020

Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein

1 reference

12 December 2020

Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response

1 reference

12 December 2020

Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis

1 reference

12 December 2020

1 reference

12 December 2020

Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease

1 reference

12 December 2020

Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease

1 reference

12 December 2020

Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V17.I47.5166

1 reference

9 August 2017

1 reference

9 August 2017

1 reference